Literature DB >> 8475112

Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection.

J Mukherjee1, L A Pirofski, M D Scharff, A Casadevall.   

Abstract

The fungus Cryptococcus neoformans is an important opportunistic pathogen for patients with AIDS. C. neoformans infections frequently involve the brain and are often fatal. In the setting of AIDS C. neoformans infections are incurable and new treatment strategies are urgently needed. Passive administration of antibody is a potential therapeutic option for the prevention and treatment of C. neoformans. The IgG1 murine monoclonal antibody 2H1 to the capsular polysaccharide of C. neoformans was studied for its ability to modify the course of lethal intracerebral cryptococcal infection in mice. Intraperitoneal administration of antibody 2H1 resulted in small, yet significant, prolongations in the average survival of mice given intracerebral infection and reduced the number of C. neoformans colonies in brain tissue. Histopathological examination of brain tissues revealed a diffuse cryptococcal meningitis with fewer organisms in the brains of mice that received antibody 2H1 than in the control group. Thus, systemic administration of a monoclonal antibody can modify the course of lethal intracerebral C. neoformans infection in mice by prolonging survival and decreasing fungal burden in brain tissues.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8475112      PMCID: PMC46356          DOI: 10.1073/pnas.90.8.3636

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  65 in total

1.  Cryptococcus neoformans antibody levels in patients with AIDS.

Authors:  F Dromer; P Aucouturier; J P Clauvel; G Saimot; P Yeni
Journal:  Scand J Infect Dis       Date:  1988

2.  Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis.

Authors:  M M Hobbs; J R Perfect; D L Granger; D T Durack
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

3.  The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection.

Authors:  R D Diamond; J E May; M A Kane; M M Frank; J E Bennett
Journal:  J Immunol       Date:  1974-06       Impact factor: 5.422

4.  Prognostic factors in cryptococcal meningitis. A study in 111 cases.

Authors:  R D Diamond; J E Bennett
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

5.  Studies on Yersinia enterocolitica. Bacteriophages liberated from chloroform treated cultures.

Authors:  B Niléhn; C Ericson
Journal:  Acta Pathol Microbiol Scand       Date:  1969

6.  Nature of the effector cells responsible for antibody-dependent cell-mediated killing of Cryptococcus neoformans.

Authors:  R D Diamond; A C Allison
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

7.  Humoral defense mechanisms in cryptococcosis: substances in normal human serum, saliva, and cerebrospinal fluid affecting the growth of Cryptococcus neoformans.

Authors:  H J Igel; R P Bolande
Journal:  J Infect Dis       Date:  1966-02       Impact factor: 5.226

8.  Immune response to Cryptococcus neoformans soluble polysaccharide. I. Serological assay for antigen and antibody.

Authors:  T R Kozel; J Cazin
Journal:  Infect Immun       Date:  1972-01       Impact factor: 3.441

9.  Immune response to Cryptococcus neoformans soluble polysaccharide: immunological unresponsiveness.

Authors:  T R Kozel; W F Gulley; J Cazin
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

10.  Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique.

Authors:  J W Murphy; G C Cozad
Journal:  Infect Immun       Date:  1972-06       Impact factor: 3.441

View more
  47 in total

1.  Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.

Authors:  Bettina C Fries; Emily Cook; Xiabo Wang; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.

Authors:  G Nussbaum; S Anandasabapathy; J Mukherjee; M Fan; A Casadevall; M D Scharff
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 3.  Antibody immunity and invasive fungal infections.

Authors:  A Casadevall
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

Review 4.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

5.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

6.  Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

8.  Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.

Authors:  J Mukherjee; L S Zuckier; M D Scharff; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole.

Authors:  A Casadevall; E D Spitzer; D Webb; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

10.  Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis.

Authors:  Karen L Wozniak; Sailatha Ravi; Sandra Macias; Mattie L Young; Michal A Olszewski; Chad Steele; Floyd L Wormley
Journal:  PLoS One       Date:  2009-09-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.